Home page | Personnel | Projects | Presentations | Publications

---

This page contains a list of JOURNAL ARTICLES GROUPED ACCORDING TO SUBJECT.
Click here for a CHRONOLOGICAL LIST OF JOURNAL ARTICLES.
Click here for a list of REVIEW ARTICLES.

Links to PubMed and to downloadable PDF files are included, if available.

---

Heparin Cofactor II
    Structure, Activity, & Biosynthesis
    Cloning & Expression
    Glycosaminoglycan-binding Site
    Mechanism of Activation
    Physiologic Function
Glycosaminoglycans
    Structure & Function
Thrombin
    Exosite Interactions
Vitronectin
    Phosphorylation
Serpin-enzyme Complex Receptor
Thrombosis Models

Tollefsen DM, Blank MK
Detection of a new heparin-dependent inhibitor of thrombin in human plasma
J Clin Invest 1981 Sep;68(3):589-96

Tollefsen DM, Majerus DW, Blank MK
Heparin cofactor II. Purification and properties of a heparin-dependent inhibitor of thrombin in human plasma
J Biol Chem 1982 Mar 10;257(5):2162-9  [Reprint PDF 2.6 MB]

Parker KA, Tollefsen DM
The protease specificity of heparin cofactor II. Inhibition of thrombin generated during coagulation
J Biol Chem 1985 Mar 25;260(6):3501-5  [Reprint PDF 2.3 MB]

Jaffe EA, Armellino D, Tollefsen DM
Biosynthesis of functionally active heparin cofactor II by a human hepatoma-derived cell line
Biochem Biophys Res Commun 1985 Oct 15;132(1):368-74

Hortin G, Tollefsen DM, Strauss AW
Identification of two sites of sulfation of human heparin cofactor II
J Biol Chem 1986 Dec 5;261(34):15827-30  [Reprint PDF 1.5 MB]

Derechin VM, Blinder MA, Tollefsen DM
Substitution of arginine for Leu444 in the reactive site of heparin cofactor II enhances the rate of thrombin inhibition
J Biol Chem 1990 Apr 5;265(10):5623-8  [Reprint PDF 1.8 MB]

top of page

Inhorn RC, Tollefsen DM
Isolation and characterization of a partial cDNA clone for heparin cofactor II1
Biochem Biophys Res Commun 1986 May 29;137(1):431-6

Blinder MA, Marasa JC, Reynolds CH, Deaven LL, Tollefsen DM
Heparin cofactor II: cDNA sequence, chromosome localization, restriction fragment length polymorphism, and expression in Escherichia coli
Biochemistry 1988 Jan 26;27(2):752-9

Herzog R, Lutz S, Blin N, Marasa JC, Blinder MA, Tollefsen DM
Complete nucleotide sequence of the gene for human heparin cofactor II and mapping to chromosomal band 22q11
Biochemistry 1991 Feb 5;30(5):1350-7  [Reprint PDF 1.1 MB]

Zhang GS, Mehringer JH, Van Deerlin VM, Kozak CA, Tollefsen DM
Murine heparin cofactor II: purification, cDNA sequence, expression, and gene structure
Biochemistry 1994 Mar 29;33(12):3632-42  [Reprint PDF 6.7 MB]

Colwell NS, Tollefsen DM
Isolation of frog and chicken cDNAs encoding heparin cofactor II
Thromb Haemost 1998 Nov;80(5):784-90  [Reprint PDF 197 KB]

top of page

Blinder MA, Andersson TR, Abildgaard U, Tollefsen DM
Heparin cofactor IIOslo. Mutation of Arg-189 to His decreases the affinity for dermatan sulfate
J Biol Chem 1989 Mar 25;264(9):5128-33  [Reprint PDF 5.4 MB]

Blinder MA, Tollefsen DM
Site-directed mutagenesis of arginine 103 and lysine 185 in the proposed glycosaminoglycan-binding site of heparin cofactor II
J Biol Chem 1990 Jan 5;265(1):286-91  [Reprint PDF 794 KB]

Whinna HC, Blinder MA, Szewczyk M, Tollefsen DM, Church FC
Role of lysine 173 in heparin binding to heparin cofactor II
J Biol Chem 1991 May 5;266(13):8129-35  [Reprint PDF 854 KB]

Colwell NS, Grupe MJ, Tollefsen DM
Amino acid residues of heparin cofactor II required for stimulation of thrombin inhibition by sulphated polyanions
Biochim Biophys Acta 1999 Apr 12;1431(1):148-56  [Reprint PDF 334 KB]

top of page

Tollefsen DM, Pestka CA, Monafo WJ
Activation of heparin cofactor II by dermatan sulfate
J Biol Chem 1983 Jun 10;258(11):6713-6  [Reprint PDF 1.6 MB]

Tollefsen DM, Pestka CA
Modulation of heparin cofactor II activity by histidine-rich glycoprotein and platelet factor 4
J Clin Invest 1985 Feb;75(2):496-501

Hortin GL, Tollefsen DM, Benutto BM
Antithrombin activity of a peptide corresponding to residues 54-75 of heparin cofactor II
J Biol Chem 1989 Aug 25;264(24):13979-82  [Reprint PDF 2.9 MB]

Van Deerlin VM, Tollefsen DM
The N-terminal acidic domain of heparin cofactor II mediates the inhibition of alpha-thrombin in the presence of glycosaminoglycans
J Biol Chem 1991 Oct 25;266(30):20223-31  [Reprint PDF 4.6 MB]

Sheehan JP, Tollefsen DM, Sadler JE
Heparin cofactor II is regulated allosterically and not primarily by template effects. Studies with mutant thrombins and glycosaminoglycans
J Biol Chem 1994 Dec 30;269(52):32747-51  [Reprint PDF 707 KB]

Han JH, Van Deerlin VM, Tollefsen DM
Heparin facilitates dissociation of complexes between thrombin and a reactive site mutant (L444R) of heparin cofactor II
J Biol Chem 1997 Mar 28;272(13):8243-9  [Reprint PDF 374 KB]

top of page

Tollefsen DM, Pestka CA
Heparin cofactor II activity in patients with disseminated intravascular coagulation and hepatic failure
Blood 1985 Oct;66(4):769-74

McGuire EA, Tollefsen DM
Activation of heparin cofactor II by fibroblasts and vascular smooth muscle cells
J Biol Chem 1987 Jan 5;262(1):169-75  [Reprint PDF 1.8 MB]

Andrew M, Paes B, Milner R, Johnston M, Mitchell L, Tollefsen DM, Powers P
Development of the human coagulation system in the full-term infant
Blood 1987 Jul;70(1):165-72

Hortin GL, Tollefsen DM, Santoro SA
Assessment of interference by heparin cofactor II in the DuPont aca antithrombin-III assay
Am J Clin Pathol 1988 Apr;89(4):515-7

Andrew M, Paes B, Milner R, Johnston M, Mitchell L, Tollefsen DM, Castle V, Powers P
Development of the human coagulation system in the healthy premature infant
Blood 1988 Nov;72(5):1651-7

He L, Vicente CP, Westrick RJ, Eitzman DT, Tollefsen DM
Heparin cofactor II inhibits arterial thrombosis after endothelial injury.
J Clin Invest 2002 Jan 15;109(2):213-219. [Reprint PDF 676 KB]

Tollefsen DM
Does heparin cofactor II modulate atherosclerosis and restenosis?
Circulation 2004 Jun 8;109(22):2682-4 [Reprint PDF 24KB]

top of page

Tollefsen DM, Peacock ME, Monafo WJ
Molecular size of dermatan sulfate oligosaccharides required to bind and activate heparin cofactor II
J Biol Chem 1986 Jul 5;261(19):8854-8  [Reprint PDF 587 KB]

Purkerson ML, Tollefsen DM, Klahr S
N-desulfated/acetylated heparin ameliorates the progression of renal disease in rats with subtotal renal ablation
J Clin Invest 1988 Jan;81(1):69-74

Maimone MM, Tollefsen DM
Activation of heparin cofactor II by heparin oligosaccharides
Biochem Biophys Res Commun 1988 May 16;152(3):1056-61

Tollefsen DM, Sugimori T, Maimone MM
Effect of low molecular weight heparin preparations on the inhibition of thrombin by heparin cofactor II
Semin Thromb Hemost 1990 Oct;16 Suppl:66-70  [Reprint PDF 424 KB]

Maimone MM, Tollefsen DM
Structure of a dermatan sulfate hexasaccharide that binds to heparin cofactor II with high affinity
J Biol Chem 1990 Oct 25;265(30):18263-71  [Reprint PDF 1.1 MB]

Gebbink RK, Reynolds CH, Tollefsen DM, Mertens K, Pannekoek H
Specific glycosaminoglycans support the inhibition of thrombin by plasminogen activator inhibitor 1
Biochemistry 1993 Feb 16;32(6):1675-80  [Reprint PDF 828 KB]

Pavao MS, Mourao PA, Mulloy B, Tollefsen DM
A unique dermatan sulfate-like glycosaminoglycan from ascidian. Its structure and the effect of its unusual sulfation pattern on anticoagulant activity
J Biol Chem 1995 Dec 29;270(52):31027-36  [Reprint PDF 302 KB]

Mourao PA, Pereira MS, Pavao MS, Mulloy B, Tollefsen DM, Mowinckel MC, Abildgaard U
Structure and anticoagulant activity of a fucosylated chondroitin sulfate from echinoderm. Sulfated fucose branches on the polysaccharide account for its high anticoagulant action
J Biol Chem 1996 Sep 27;271(39):23973-84  [Reprint PDF 467 KB]

Pavao MS, Aiello KR, Werneck CC, Silva LC, Valente AP, Mulloy B, Colwell NS, Tollefsen DM, Mourao PA
Highly sulfated dermatan sulfates from Ascidians. Structure versus anticoagulant activity of these glycosaminoglycans
J Biol Chem 1998 Oct 23;273(43):27848-57  [Reprint PDF 390 KB]

Martin DJ, Toce JA, Anevski PJ, Tollefsen DM, Abendschein DR
Anticoagulant and antithrombotic activity of maltodapoh, a novel sulfated tetrasaccharide
J Pharmacol Exp Ther 1999 Feb;288(2):516-21  [Reprint PDF 141 KB]

Vicente CP, He L, Pavao MS, Tollefsen DM
Antithrombotic activity of dermatan sulfate in heparin cofactor II-deficient mice.
Blood 2004 Dec 15;104(13):3965-70.  [Reprint PDF 204KB]

Pomin VH, Pereira MS, Valente AP, Tollefsen DM, Pavao MS, Mourao PA
Selective cleavage and anticoagulant activity of a sulfated fucan: stereospecific removal of a 2-sulfate ester from the polysaccharide by mild acid hydrolysis, preparation of oligosaccharides, and heparin cofactor II-dependent anticoagulant activity.
Glycobiology 2005 Apr;15(4):369-81.  [Reprint PDF 468KB]

top of page

Sheehan JP, Wu Q, Tollefsen DM, Sadler JE
Mutagenesis of thrombin selectively modulates inhibition by serpins heparin cofactor II and antithrombin III. Interaction with the anion-binding exosite determines heparin cofactor II specificity
J Biol Chem 1993 Feb 15;268(5):3639-45  [Reprint PDF 2.3 MB]

Colwell NS, Tollefsen DM, Blinder MA
Identification of a monoclonal thrombin inhibitor associated with multiple myeloma and a severe bleeding disorder
Br J Haematol 1997 Apr;97(1):219-26  [Reprint PDF 0.9 MB]

Han JH, Cote HC, Tollefsen DM
Inhibition of meizothrombin and meizothrombin(desF1) by heparin cofactor II
J Biol Chem 1997 Nov 7;272(45):28660-5  [Reprint PDF 381 KB]

Han JH, Tollefsen DM
Ligand binding to thrombin exosite II induces dissociation of the thrombin-heparin cofactor II(L444R) complex
Biochemistry 1998 Mar 3;37(9):3203-9  [Reprint PDF 89 KB]

Colwell NS, Blinder MA, Tsiang M, Gibbs CS, Bock PE, Tollefsen DM
Allosteric effects of a monoclonal antibody against thrombin exosite II
Biochemistry 1998 Oct 27;37(43):15057-65  [Reprint PDF 189 KB]

Lian F, He L, Colwell NS, Lollar P, Tollefsen DM
Anticoagulant activities of a monoclonal antibody that binds to exosite II of thrombin.
Biochemistry 2001 Jul 24;40(29):8508-13  [Reprint PDF 59 KB]

Verhamme IM, Olson ST, Tollefsen DM, Bock PE
Binding of exosite ligands to human thrombin: Re-evaluation of allosteric linkage between thrombin exosites I and II.
J Biol Chem 2002 Mar 1;277(9):6788-6798  [Reprint PDF 216 KB]

top of page

McGuire EA, Peacock ME, Inhorn RC, Siegel NR, Tollefsen DM
Phosphorylation of vitronectin by a protein kinase in human plasma. Identification of a unique phosphorylation site in the heparin-binding domain
J Biol Chem 1988 Feb 5;263(4):1942-5  [Reprint PDF 2.5 MB]

Tollefsen DM, Weigel CJ, Kabeer MH
The presence of methionine or threonine at position 381 in vitronectin is correlated with proteolytic cleavage at arginine 379
J Biol Chem 1990 Jun 15;265(17):9778-81  [Reprint PDF 1.0 MB]

Mehringer JH, Weigel CJ, Tollefsen DM
Cyclic AMP-dependent protein kinase phosphorylates serine378 in vitronectin
Biochem Biophys Res Commun 1991 Aug 30;179(1):655-60  [Reprint PDF 528 KB]

top of page

Joslin G, Wittwer A, Adams S, Tollefsen DM, August A, Perlmutter DH
Cross-competition for binding of alpha 1-antitrypsin (alpha 1 AT)-elastase complexes to the serpin-enzyme complex receptor by other serpin-enzyme complexes and by proteolytically modified alpha 1 AT
J Biol Chem 1993 Jan 25;268(3):1886-93  [Reprint PDF 6.4 MB]

Maekawa H, Tollefsen DM
Role of the proposed serpin-enzyme complex receptor recognition site in binding and internalization of thrombin-heparin cofactor II complexes by hepatocytes
J Biol Chem 1996 Aug 2;271(31):18604-9  [Reprint PDF 609 KB]

top of page

He L, Vicente CP, Westrick RJ, Eitzman DT, Tollefsen DM
Heparin cofactor II inhibits arterial thrombosis after endothelial injury.
J Clin Invest 2002 Jan 15;109(2):213-219. [Reprint PDF 676 KB]

He L, Pappan LK, Grenache DG, Li Z, Tollefsen DM, Santoro SA, Zutter MM
The contributions of the {alpha}2{beta}1 integrin to vascular thrombosis in vivo.
Blood 2003 Nov 15;102(10):3652-3657.  [Reprint PDF 232KB]

Vicente CP, He L, Pavao MS, Tollefsen DM
Antithrombotic activity of dermatan sulfate in heparin cofactor II-deficient mice.
Blood 2004 Dec 15;104(13):3965-70.  [Reprint PDF 204KB]

Chen HH, Vicente CP, He L, Tollefsen DM, Wun TC
Fusion proteins comprising annexin V and Kunitz protease inhibitors are highly potent thrombogenic site-directed anticoagulants.
Blood 2005 May 15;105(10):3902-9.  [Reprint PDF 172KB]  [Comment PDF 80KB]

top of page